Drug Approval | July 14, 2022
Shilpa Medicare’s Unit VI, Bengaluru facility has been issued UK MHRA GMP
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The compendium was released by Suman Bery, Vice-Chairman, NITI Aayog and Dr. Munjpara Mahendrabhai Kalubhai, Minister of State for Ayush and WCD.
The company is now introducing the product into the India pharmaceutical market.
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
Subscribe To Our Newsletter & Stay Updated
